MENS.US Jyong Biotech Ltd. Ordinary Shares

Healthcare Biotechnology USA Stocks
1.80 USD
Close of Nov 15, 2026
1.43 38.88
Market cap
USD 134M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is MENS.US undervalued?

Graham number

The Graham number of Jyong Biotech Ltd. Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Jyong Biotech Ltd. Ordinary Shares fundamental analysis

No fundamental analysis for Jyong Biotech Ltd. Ordinary Shares yet.

Jyong Biotech Ltd. Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome. The company was founded in 2002 and is…

Full company profile